Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
mixture
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01753908CT.gov Broccoli Sprout Extract in Treating Patients With Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Ductal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ae-Broccoli (this asset) | Roswell Park Cancer Institute | Early P1 | CC · 43 |
| Adriamycin | Sanofi | P2 | CCC |
| Docetaxel | Sanofi | P2 | CCC |
| Exemestane | Dana-Farber Cancer Institute | P2 | CCC |
| Tamoxifen | Dana-Farber Cancer Institute | P2 | CCC |
| ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE | H. Lee Moffitt Cancer Center and Research Institute | P1/2 | CCC |
| Survivin Peptide Vaccine | University of Pennsylvania | P1 | CC |
| Htert | University of Pennsylvania | P1 | CC |
| Pembrolizumab | Carisma Therapeutics Inc | P1 | CC |
+2 more in the Breast Ductal Adenocarcinoma cohort
Other indications for Ae-Broccoli
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P2 | CCC · 53 |
| Ductal Breast Carcinoma In Situ | — | Early P1 | CC · 43 |
| Estrogen-Receptor Negative Breast Cancer | — | Early P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ae-Broccoli in Breast Ductal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ae-broccoli-breast-ductal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →